Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek(University Hospital Cologne), Kirsten Fischer(University of Cologne), Guenter Fingerle-Rowson(University of Cologne), AM Fink(University Hospital Cologne), R. Busch, Jiřı́ Mayer(University Hospital Brno), M. Hensel(Heidelberg University), Georg Hopfinger(Hanusch Hospital), G Hess(Johannes Gutenberg University Mainz), Ulrich von Grünhagen(Praxis), Michèle Bergmann(Ludwig-Maximilians-Universität München), J. Catalano(Frankston Hospital), Pier Luigi Zinzani(University of Bologna), Federico Caligaris‐Cappio(San Raffaele University of Rome), JF Seymour(University of Melbourne), A Berrébi(Kaplan Medical Center), Ulrich Jäger(Medical University of Vienna), Bruno Cazin(Hôpital Claude Huriez), Marek Trněný(Charles University), Anne Westermann(University Hospital Cologne), C-M Wendtner(University Hospital Cologne), BF Eichhorst(University Hospital Cologne), Peter Staib(Sankt-Antonius-Hospital Eschweiler), Andreas Bühler(Universität Ulm), Dirk Winkler(Universität Ulm), Thorsten Zenz(Universität Ulm), Sebastian Böttcher(University Hospital Schleswig-Holstein), Matthias Ritgen(University Hospital Schleswig-Holstein), Myriam Mendila(Roche (Switzerland)), Michael Kneba(University Hospital Schleswig-Holstein), Hartmut Döhner(Universität Ulm), S. Stilgenbauer(Universität Ulm)
Cited by 1,863